CHRS Coherus BioSciences Inc.

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 5:15 p.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website: . This webcast will be available for replay until February 10, 2025.

Coherus Contact Information:

For Investors:

Jodi Sievers

VP, Investor Relations & Corporate Communications



EN
08/01/2025

Underlying

CHRSCoherus BioSciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coherus BioSciences Inc.

 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results ...

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025 REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call Information When: Monday, March 10, 2025, starting at 5:00 p.m....

March 3, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Management to Participate at the 45th Annual TD Cowen Health C...

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in a fireside chat presentation at the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025, at 11:50 a.m., Eastern time. A live audio webcast will be accessible through a link posted on the “Events and Presentations” section of the Coherus’ investor website: . A replay of the presentation will be available on this same website...

February 24, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data ...

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 – Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor activity was observed across both viral and non-viral etiologies – – Data support continued evaluation of casdozokitug with VEGF and PD-(L)1 blockade in HCC – - Randomized Phase 2 trial evaluating casdozokitug/bevacizumab/toripalimab now open for enroll...

January 22, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcar...

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 5:15 p.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website: . This webcast will be available for replay until February 10, 2025. Coherus Contact Informa...

January 8, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Pati...

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 - Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-antagonistic antibody, in combination...

December 18, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch